Peer review

Amy­lyx wel­comes for­mer Al­ny­lam ex­ec to help ex­pand Re­lyvrio; Amarin plugs in an in­ter­im chief

Masako Nakamura will lead Relyvrio’s march to key regions as Amylyx’s general manager and head of the Asia Pacific and Latin America international markets. Nakamura, the SVP, head of Asia at Alnylam from 2018-21, tackled a similar gig as GM, Asia with Aegerion Pharmaceuticals and had a 10-year career at Genzyme. Canada approved Amylyx’s ALS drug, known in that country as Albrioza, in June 2022, while the FDA gave it the go-ahead in September following an unconventional second adcomm.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 170,300+ biopharma pros reading Endpoints daily — and it's free.

Leg­end's new CMO will bring in more cell ther­a­py part­ners; Pre­ci­sion founders get back in Tune to­geth­er

Mythili Koneru returned to her childhood stomping grounds of New Jersey last Friday to lead the medical operations at Legend Biotech, where she’ll drive the cell therapy maker’s expansion into solid tumors and off-the-shelf options.

Legend will tap into her business development chops, built during a stint at Eli Lilly, as it looks to ink more partnerships on the back of its successful collaboration with Johnson & Johnson‘s Janssen, which helped solidify the biotech as one of the early leaders in cell therapy with the approval of Carvykti.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 170,300+ biopharma pros reading Endpoints daily — and it's free.

Af­ter decades in Big Phar­ma, Kel­ly Page heads to 'growth stage'; Al­lied with No­var­tis, Bi­cy­cle se­lects de­vel­op­ment chief

Following a decades-long career in Big Pharma, Kelly Page wanted to use her research and commercial experience to help a small company grow.

Last Tuesday, she started at Arvinas, a Pfizer-partnered biotech looking to harness the body’s protein disposal system to degrade disease-causing proteins. She has taken the role of senior VP and global head of oncology strategy and program leadership, a field that’s motivated her personally since three close relatives were diagnosed with lymphoma in 1999.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 170,300+ biopharma pros reading Endpoints daily — and it's free.

Jim Mullen scours pri­vate eq­ui­ty deals amid biotech win­ter; Ex-Ab­b­Vie med­ical chief suc­ceeds Brig­gs Mor­ri­son at Syn­dax

Jim Mullen is in, by his count, his third or fourth “long, cold winter in biotech investing.” But that’s not stopping the ex-Biogen CEO from finding flickers of light.

Earlier this week, private equity player Advent International announced that Mullen had joined as an operating partner — its term for independent advisors who bring industry experience.

Mullen told Endpoints News in an interview that he’s been doing advising work for a number of private equity firms and enjoyed it.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 170,300+ biopharma pros reading Endpoints daily — and it's free.

Image courtesy of The Janssen Pharmaceutical Companies of Johnson & Johnson.

Pro­tect­ing the glob­al phar­ma­ceu­ti­cal in­no­va­tion ecosys­tem – what’s at stake?

We are living in a new era of healthcare that is rapidly advancing progress impacting patient outcomes and experiences. We’ve seen a remarkable pace of transformational innovation, applied research, and advanced clinical development over the last decade.

Despite this tremendous progress, there is much more work to be done, and patients are counting on us – now more than ever – to continue that momentum. At the heart of our industry is a focus on developing and delivering medicines for some of the world’s most challenging diseases, including those that have few or no effective treatments today.